Robin LaChapelle - 11 Jul 2025 Form 4 Insider Report for ArriVent BioPharma, Inc. (AVBP)

Role: Chief Operating Officer
Signature: By: /s/ James Kastenmayer, Attorney-in-Fact for Robin LaChapelle
Issuer symbol: AVBP
Transactions as of: 11 Jul 2025
Net transactions value: +$25,429
Form type: 4
Filing time: 15 Jul 2025, 07:00:15 UTC
Previous filing: 14 Feb 2025
Next filing: 04 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
LaChapelle Robin	Chief Operating Officer	C/O ARRIVENT BIOPHARMA, INC., 18 CAMPUS BOULEVARD, SUITE 100, NEWTOWN SQUARE	By: /s/ James Kastenmayer, Attorney-in-Fact for Robin LaChapelle	15 Jul 2025	0002009136

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AVBP	Common Stock	Options Exercise	$4,674	+2,050	+1.6%	$2.28	126,633	11 Jul 2025	Direct
transaction	AVBP	Common Stock	Options Exercise	$5,928	+2,600	+2.1%	$2.28	129,233	11 Jul 2025	Direct
transaction	AVBP	Common Stock	Options Exercise	$14,827	+6,503	+5%	$2.28	135,736	11 Jul 2025	Direct
holding	AVBP	Common Stock						394,477	11 Jul 2025	Held by The MAKS Yao Trust	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVBP	Stock Option (right to buy)	Options Exercise	$0	-2,050	-83%	$0.000000	410	11 Jul 2025	Common Stock	2,050	$2.28	Direct	F2
transaction	AVBP	Stock Option (right to buy)	Options Exercise	$0	-2,600	-17%	$0.000000	12,873	11 Jul 2025	Common Stock	2,600	$2.28	Direct	F3
transaction	AVBP	Stock Option (right to buy)	Options Exercise	$0	-6,503	-51%	$0.000000	6,370	11 Jul 2025	Common Stock	6,503	$2.28	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. The Reporting Person does not have a pecuniary interest in and disclaims beneficial ownership of the shares held by The MAKS Yao Trust.
F2	The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F3	The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.